Maria Raitses-Gurevich
Overview
Explore the profile of Maria Raitses-Gurevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yablecovitch D, Nadler M, Ben-Horin S, Picard O, Yavzori M, Fudim E, et al.
Cancer Med
. 2024 Sep;
13(17):e70144.
PMID: 39263943
Aims And Background: Matrix metalloproteinase-7 (MMP-7) and Syndecan-1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as...
2.
Zogopoulos G, Haimi I, Sanoba S, Everett J, Wang Y, Katona B, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):158-166.
PMID: 38626807
Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To...
3.
Golan T, Raitses-Gurevich M, Beller T, Carroll J, Brody J
Cancer Treat Res
. 2023 Nov;
186:125-142.
PMID: 37978134
A subset of patients with pancreatic adenocarcinomas (PDAC) harbor mutations that are exploitable in the context of DNA-damage response and repair (DDR) inhibitory strategies. Between 8-18% of PDACs harbor specific...
4.
Laish I, Schechter M, Dancour A, Lieberman S, Levi Z, Goldberg Y, et al.
Cancer
. 2023 Oct;
130(2):256-266.
PMID: 37861363
Background: Surveillance of high-risk individuals for pancreatic ductal adenocarcinoma (PDAC) is recommended. This study aimed to determine the prevalence and outcomes of PDAC and its precursor lesions in BRCA1/2 pathogenic...
5.
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, et al.
Cancer Discov
. 2023 Jul;
13(8):1826-1843.
PMID: 37449843
Significance: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs...
6.
Gavish A, Tyler M, Greenwald A, Hoefflin R, Simkin D, Tschernichovsky R, et al.
Nature
. 2023 May;
618(7965):598-606.
PMID: 37258682
Each tumour contains diverse cellular states that underlie intratumour heterogeneity (ITH), a central challenge of cancer therapeutics. Dozens of recent studies have begun to describe ITH by single-cell RNA sequencing,...
7.
Jbara A, Lin K, Stossel C, Siegfried Z, Shqerat H, Amar-Schwartz A, et al.
Nature
. 2023 Mar;
617(7959):147-153.
PMID: 36949200
Pancreatic ductal adenocarcinoma (PDA) is characterized by aggressive local invasion and metastatic spread, leading to high lethality. Although driver gene mutations during PDA progression are conserved, no specific mutation is...
8.
Yablecovitch D, Ben-Horin S, Picard O, Yavzori M, Fudim E, Nadler M, et al.
Clin Transl Gastroenterol
. 2022 Mar;
13(5):e00473.
PMID: 35297817
Introduction: Syndecan-1 (SDC1) has multiple functions in tumorigenesis in general and specifically in pancreatic cancer. We aimed to evaluate SDC1 as a diagnostic and prognostic biomarker in patients with pancreatic...
9.
Golan T, Atias D, Stossel C, Raitses-Gurevich M
Adv Drug Deliv Rev
. 2021 Feb;
171:257-265.
PMID: 33617901
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease. The majority of patients diagnosed at an advanced, metastatic stage, and poor overall survival rates. The most clinically meaningful subtype obtained from...
10.
Golan T, OKane G, Denroche R, Raitses-Gurevich M, Grant R, Holter S, et al.
Gastroenterology
. 2021 Feb;
160(6):2119-2132.e9.
PMID: 33524400
Background And Aims: Homologous recombination deficiency (HRD) in pancreatic ductal adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in BRCA1, BRCA2, and PALB2. Methods: We interrogated whole genome sequencing...